On April 4, 2022 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported abstract acceptance with a poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, to be held in New Orleans from April 8-13, 2022 (Press release, Spectrum Pharmaceuticals, APR 4, 2022, View Source [SID1234611399]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Session title and information for the poster is listed below and is now available on the AACR (Free AACR Whitepaper) online itinerary planner.

Predictive ability of circulating tumor DNA by Guardant360 in poziotinib-treated patients with NSCLC harboring HER2 exon 20 insertion mutations
Session Title: PO.CL11.03 – Cell-Free DNA 2
Session Date and Time: Tuesday, April 12, 2022; 1:30 PM – 5:00 PM CT
Location: New Orleans Convention Center, Section 31
Abstract / Poster: 3400 / 6

Copies of the presentation will be available on Spectrum’s website at View Source following presentation at the meeting.